Netherlands Archives

News and Trends 15 Nov 2022

Fooditive takes world first bee-free honey a step closer

Large scale production trials of the first bee-free honey will start in the New Year thanks to Dutch-based ingredients company, Fooditive. The process of mass-producing a bio-identical honey means that the need to intensively farm honeybees will be eliminated and Fooditive aims to beat a scalable, provenanced supply. Not only will it provide the benefits […]

November 15, 2022 - 2 minutesmins - By Liza Laws

More News! 8 Nov 2022

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […]

November 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

Lipum starts chronic inflammatory disease drug study

Lipum AB (publ) says its phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. A first dose group of eight healthy volunteers have received a dose, with two volunteers receiving placebo. Lipum’s drug candidate SOL-116 is a fully humanized antibody that is intended to address a major […]

November 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Enzyre secures €12M series A funding to help hemophilia patients test from home

Dutch company, Enzyre, which is developing ambulant diagnostic technology for blood coagulation testing, today (November 2) announced it has successfully raised €12 million ($11.9 million) in series A financing. The round was led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Ophthalmology biopharma company Oculis combines with EBAC

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named Oculis Holding SA and will work to accelerate the development […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

Accelerated application for drug to help immunodeficiency submitted by Pharming

A marketing authorization application (MAA) has been submitted by Dutch company Pharming Group, to the European Medicines Agency (EMA) for a rare, primary immunodeficiency in adults and adolescents 12 years and older. Activated phosphonide 3-kinase delta syndrome (APDS), first discovered in 2013, is caused by genetic variants in either one of two identified genes known […]

October 11, 2022 - 4 minutesmins - By Liza Laws

Best in Biotech 7 Oct 2022

Needle-free diabetes care: 7 devices that painlessly monitor blood sugar

Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be […]

October 7, 2022 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2022

Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract

Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Kling Biotherapeutics doses first patient in advanced solid tumor trial

Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care. KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by […]

September 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Sep 2022

Optics11 Life receives €5 million in funding for drug development and rollout of products

Expanded offerings for drug development and regenerative medicines will be the focus of €5 million ($4.8 million) funding raised by Optics11 Life. The funding from Forward.ONE and returning investor, Value Creation Capital, was announced today (September 28) and will support the rollout of new products applying the company’s technology for experiments at scale requiring high-throughput […]

September 28, 2022 - 2 minutesmins - By Liza Laws

Cleara Biotech closes $2.5M round for senescence treatment

News and Trends 28 Sep 2022

Cleara Biotech closes $2.5M seed financing round to progress senescence treatment

Cleara Biotech has closed a $2.5 million seed financing round that it will use for progress its compounds toward clinical development. The company that develops therapies for treating different pathologies of scarred cellular senescence including late-stage cancer and chronic diseases made the announcement yesterday (September 27). The financing round earlier in the year was led […]

September 28, 2022 - 4 minutesmins - By Liza Laws

kai pinkernell glycostem nk cell therapy

Interview 27 Sep 2022

Natural killer cells: a thriving frontier in allogeneic cell therapy

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […]

September 27, 2022 - 6 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us